Cempra Company Profile (NASDAQ:CEMP)

Analyst Ratings

Consensus Ratings for Cempra (NASDAQ:CEMP) (?)
Ratings Breakdown: 2 Hold Rating(s), 9 Buy Rating(s)
Consensus Rating:Buy (Score: 2.82)
Consensus Price Target: $36.27 (101.52% upside)

Analysts' Ratings History for Cempra (NASDAQ:CEMP)
Show:
DateFirmActionRatingPrice TargetActions
7/12/2016JPMorgan Chase & Co.Initiated CoverageOverweight$31.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/5/2016WBB SecuritiesReiterated RatingBuy$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/24/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/24/2016Needham & Company LLCReiterated RatingBuy$48.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/24/2016Stifel NicolausLower Price TargetBuy$51.00 -> $47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Roth CapitalInitiated CoverageBuy$37.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/29/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Janney Montgomery ScottReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/2/2016Leerink SwannReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2016Robert W. BairdReiterated RatingBuy$38.00 -> $33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/16/2015Morgan StanleyUpgradeEqual Weight -> Overweight$25.00 -> $38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/18/2015SunTrust Banks Inc.Reiterated RatingBuy$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/5/2015Ladenburg ThalmannReiterated RatingBuy$17.00 -> $34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Cempra (NASDAQ:CEMP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/27/2016Q2($0.67)N/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2016Q1($0.63)($0.61)$3.94 million$2.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2016Q4($0.59)($0.48)$3.89 million$5.79 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/22/2015Q315($0.52)($0.63)$4.70 million$2.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2015Q2($0.42)($0.57)$4.21 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q1($0.43)($0.41)$2.90 million$13.96 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2015Q414($0.49)($0.46)$3.19 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2014Q314($0.56)($0.34)$7.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2014Q214($0.56)($0.49)$2.56 million$1.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/29/2014Q114($0.48)($0.51)$2.10 million$3.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q413($0.42)($0.51)$1.25 million$2.07 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2013Q313($0.29)($0.41)$0.46 million$1.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2013Q3 2013($0.42)($0.16)$5.13 million$4.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2012Q312($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cempra (NASDAQ:CEMP)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20166($0.61)($0.48)($0.56)
Q2 20166($0.68)($0.44)($0.58)
Q3 20165($0.78)($0.60)($0.70)
Q4 20166($0.94)$2.54$0.30
Q1 20171($0.91)($0.91)($0.91)
Q2 20171($0.83)($0.83)($0.83)
Q3 20171($0.68)($0.68)($0.68)
Q4 20171($0.56)($0.56)($0.56)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cempra (NASDAQ:CEMP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cempra (NASDAQ:CEMP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/1/2016David MooreInsiderBuy500$16.18$8,090.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Dov A. Md GoldsteinDirectorSell842$30.06$25,310.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015David W. OldachinsiderSell10,000$30.27$302,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/9/2015David W. OldachinsiderSell12,200$28.78$351,116.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/26/2015Garheng KongDirectorBuy2,830$17.43$49,326.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/22/2015Dov A Md GoldsteinDirectorSell50,000$35.74$1,787,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2014John JohnsonDirectorBuy10,000$9.10$91,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2013P Sherrill NeffDirectorBuy265,000$7.00$1,855,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cempra (NASDAQ:CEMP)
DateHeadline
07/25/16 02:23 PMCan Shares Of Cempra, Inc. (NASDAQ:CEMP) Hit $51? - Investor Newswire
07/25/16 06:30 AMCempra to Report Second Quarter 2016 Financial Results - [GlobeNewswire] - CHAPEL HILL, N.C., July 25, 2016-- Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, ...
07/23/16 07:26 AMAnalysts Take on Earnings: GrubHub Inc. (NYSE:GRUB), Cempra, Inc. (NASDAQ:CEMP), Huntsman Corporation ... - Engelwood Daily
07/21/16 08:42 PMCempra, Inc. (NASDAQ:CEMP): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 08:42 PMAisling Capital LLC Decreased Stake in Cempra INC (NASDAQ:CEMP) by $17.00 Million as Shares Declined - Press Telegraph
07/21/16 08:42 PMCempra Inc (NASDAQ:CEMP) Stock Technicals at Critical Inflection Point - CML News
07/20/16 11:12 AMEquity Roundup: Stock Performance Focus on Cempra, Inc. (NASDAQ:CEMP) - Press Telegraph
07/20/16 11:12 AMStock Moving Lower for the Month; Investor Update on Cempra, Inc. (NASDAQ:CEMP) - Engelwood Daily
07/20/16 11:12 AMCempra Inc Can't Be More Risky. Trades Sigfnicicantly Lower - Consumer Eagle
07/20/16 11:12 AMBroker Outlook For Cempra, Inc. (NASDAQ:CEMP) - Fiscal Standard
07/20/16 07:12 AMCempra, Inc. breached its 50 day moving average in a Bearish Manner : CEMP-US : July 20, 2016 -
07/19/16 09:24 AMIs $51 Price Target Attainable For Cempra, Inc. (NASDAQ:CEMP)? - Investor Newswire
07/19/16 09:24 AMAre Analysts Bullish Cempra Inc (NASDAQ:CEMP) After Last Week? - Press Telegraph
07/19/16 09:24 AMEarnings Focus and Crowd Sourced Sentiment Review for Cempra, Inc. (NASDAQ:CEMP) - TGP
07/18/16 08:11 AMStock in Positive Territory for the Quarter: Cempra, Inc. (NASDAQ:CEMP) - Engelwood Daily
07/18/16 08:11 AMShare Performance Summary for: Cempra, Inc. (NASDAQ:CEMP) - Press Telegraph
07/14/16 03:13 PMCempra, Inc. (NASDAQ:CEMP) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/14/16 03:13 PMCempra Inc Stock Momentum Hits Strength - CML News
07/14/16 09:16 AMAnalyst Target and Average Rating Watch: Cempra, Inc. (NASDAQ:CEMP) - Press Telegraph
07/14/16 09:16 AMAisling Capital LLC Decreased Stake in Cempra INC (NASDAQ:CEMP) by $17.00 Million as Shares Declined - Consumer Eagle
07/14/16 08:50 AMAntibiotic for Treatment of Superbugs Could Send Cempra Shares Soaring -
07/13/16 08:34 PMCempra Inc. (CEMP) is Trading Higher on Unusual Volume for July 12 - Equities.com
07/13/16 11:13 AMSession Volatility Review for: Cempra, Inc. (NASDAQ:CEMP) - Engelwood Daily
07/13/16 11:13 AMShares Losing Ground for the Month; Investor Alert on Cempra, Inc. (NASDAQ:CEMP) - Engelwood Daily
07/13/16 11:13 AMAnalyst Update: Spark Therapeutics Inc, Cempra Inc, and Medivation Inc - Schaeffers Research (blog)
07/13/16 11:13 AMCempra Is 'A Good Drug For Bad Bugs,' Says JPMorgan - Benzinga
07/12/16 07:22 AMCempra, Inc. (NASDAQ:CEMP) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/12/16 07:22 AMCempra Inc indicated as Overweight By JP Morgan - Fiscal Standard
07/12/16 05:17 AMCoverage initiated on Cempra by JP Morgan -
07/11/16 03:06 PMStock Performance Rundown on: Cempra, Inc. (NASDAQ:CEMP) - Press Telegraph
07/11/16 03:06 PMStrong Sell Calls For Cempra, Inc. (NASDAQ:CEMP) At 0 - Investor Newswire
07/10/16 03:00 PMNext Weeks Broker Price Targets For Cempra, Inc. (NASDAQ:CEMP) - Fiscal Standard
07/10/16 07:47 AMPeople in Business
07/08/16 12:04 PMCEMPRA, INC. Financials -
07/07/16 08:26 PMCan Cempra, Inc. (NASDAQ:CEMP) Improve on the Earnings Front? - Engelwood Daily
07/07/16 03:11 PMCompany Stock Focus for Cempra, Inc. (NASDAQ:CEMP): Which Way Will Shares Head? - Press Telegraph
07/06/16 08:55 PMStock Tracking Down This Month; Investor Alert on Cempra, Inc. (NASDAQ:CEMP) - Engelwood Daily
07/06/16 08:55 PMBiotech Movers: Insys Therapeutics Inc (INSY) and Cempra Inc (CEMP) - Insider Monkey (blog)
07/06/16 03:32 PMCEMPRA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
07/05/16 03:07 PMBiotech Movers: Insys Therapeutics Inc (NASDAQ:INSY) and Cempra Inc (NASDAQ:CEMP) - Market Exclusive
07/05/16 07:58 AMCempra Says FDA Accepts Solithera NDA Community-Acquired Bacterial Pneumonia Treatment - Cempra, Inc. (NASDAQ: CEMP) said that its New Drug Applications (NDAs) for SolitheraTM (solithromycin) approval as a treatment for community-acquired bacterial pneumonia (CABP) were accepted for filing by the Food and Drug Administration. Cempra said the acceptance of two NDAs, one for the intravenous formulations while the other for oral capsules, indicated that the applications were sufficiently complete to permit a substantive review by the FDA. The company's president and CEO, ...Full story available on Benzinga.com
07/05/16 07:55 AMCempra, Inc. (NASDAQ:CEMP) Expected to Reach Highs Of $51 - Investor Newswire
07/05/16 07:55 AMShare Performance Recap for: Cempra, Inc. (NASDAQ:CEMP) - Press Telegraph
07/05/16 07:55 AMCompany Update (NASDAQ:CEMP): Cempra Inc Announces FDA Acceptance of Solithera™ NDA to Treat Community ... - Smarter Analyst
07/05/16 06:02 AM7:02 am Cempra announces FDA acceptance of Solithera New Drug Applications in the treatment of community-acquired bacterial pneumonia -
07/05/16 06:00 AMCempra Announces FDA Acceptance of Solithera™ New Drug Applications in the Treatment of Community-Acquired Bacterial Pneumonia - [GlobeNewswire] - CHAPEL HILL, N.C., July 05, 2016-- Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, ...
07/02/16 10:44 AMCompany Stock Lower on the Week Cempra, Inc. (NASDAQ:CEMP) - Engelwood Daily
06/30/16 03:24 PMCempra : Technical Coverage of Biotechnology Stocks - Agenus, BioCryst Pharma, Cempra, and Hemispherx Biopharma
06/30/16 10:58 AMWill Cempra, Inc. (NASDAQ:CEMP) Surprise Analysts? - Investor Newswire
06/30/16 10:58 AMRecently Issued Stock Ratings For Cempra, Inc. (NASDAQ:CEMP) - Fiscal Standard

Social

About Cempra

Cempra logoCempra, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company's lead product, solithromycin (CEM-101), is being developed in oral capsules, intravenous (IV), and suspension formulations, for the treatment of community-acquired bacterial pneumonia (CABP), as well as for the treatment of gonorrhea and other indications. Solithromycin has therapeutic potential and the spectrum of activity to target pathogenic bacteria. The Company also focuses on developing Taksta, which is an antibiotic known as fusidic acid, and is indicated as an oral treatment of acute bacterial skin and skin structure infections (ABSSSI).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: CEMP
  • CUSIP: 15130J10
Key Metrics:
  • Previous Close: $18.00
  • 50 Day Moving Average: $18.06
  • 200 Day Moving Average: $17.64
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $867.60M
  • Beta: 1.31
  • Current Year EPS Consensus Estimate: $-2.58 EPS
  • Next Year EPS Consensus Estimate: $-2.58 EPS
Additional Links:
Cempra (NASDAQ:CEMP) Chart for Monday, July, 25, 2016